Skip to main content

Table 2 Rates and reasons for discontinuation

From: Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

 

Etanercept cohort (N = 2725)

Discontinuations

1655 (60.7)

Remission

652 (23.9)

Inefficacy

594 (21.8)

Intolerance

192 (7.1)

Patient’s demand

504 (18.5)

Others

287 (10.5)

  1. Data are shown as n (%). Multiple reasons could be given
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us